Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Tumors With NF1 Mutations (MATCH Subprotocol S1)
NCT04439318Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in malignant solid neoplasm, lymphoma, refractory malignant solid neoplasm and 1 more, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 3 years. Started Feb 2016; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
malignant solid neoplasmlymphomarefractory malignant solid neoplasmmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439318.